New Perspectives on Targeted Therapy in Ovarian Cancer
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".
Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 3250
Special Issue Editor
2. College of Pharmacy, Health Professions Division, Nova Southeastern University, Fort Lauderdale, FL 33314, USA
Interests: drug discovery, anti-VEGF development, biological drug discovery; targeted therapy; pre-clinical trials; glioblastoma, neuroblastoma, prostate cancer, ovarian cancer; epigenetics; histone modifications; HDAC inhibitors
Special Issue Information
Dear Colleagues,
Ovarian cancer is the second most common and the most lethal gynecologic malignancy among women in the western world. Late detection of ovarian cancer is related to the lack of early warning symptoms, and, as a consequence, about 70% of ovarian cancers are diagnosed at an advanced stage with a bad prognosis. It is difficult to cure late-stage ovarian cancer; however, recent advancements in ovarian cancer treatments are helping to make it a manageable chronic disease. This is mostly due to the current progress with surgical technology, contemporary regimens of systemic treatment, as well as the introduction of new drugs. However, many new drugs and treatment strategies are under development. Some of the examples of new drugs under development for ovarian cancer include anti-angiogenic factors, inhibitors of growth factor signaling, polyADP-ribose polymerase (PARP) inhibitors, folate receptor inhibitors, and DNA repair strategies. In addition, immunotherapeutic approaches are also being tested. Though many of these new agents and therapeutic approaches are not shown to effectively cure ovarian cancer, they lead to the extension of patients’ survival or the delay of the recurrence, or the stabilization, of the disease.
In this Special Issue of Medicina, we will discuss the current advances in therapy for ovarian cancer, highlight some of the new therapeutic approaches, and their present status.
Prof. Dr. Appu Rathinavelu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Ovarian cancer
- Biological drugs
- Targeted therapy
- Clinical trials
- Epithelial ovarian cancer (EOC)
- anti-EGFR
- Epigenetics
- Histone modifications
- HDAC inhibitors.
